Lu AF90103 / Lundbeck - LARVOL DELTA

Advancements in NMDA Receptor-Targeted Antidepressants: From d-Cycloserine Discovery to Preclinical Efficacy of Lu AF90103. (PubMed, J Med Chem) - "The discovery of d-cycloserine (DCS), a partial agonist of the NMDA receptor that exhibits antidepressant effects without the psychotomimetic effects of ketamine, has fueled interest in new NMDA-targeting antidepressants. Subsequent investigations led us to 42e (Lu AF90103), a methyl ester prodrug of 42d capable of penetrating the blood-brain barrier, as confirmed by rat microdialysis studies. In different rat in vivo models relevant to neuropsychiatric diseases, administering 42e led to 42d demonstrating both acute effects, observed in a seizure model and EEG, and lasting effects in the stress-sensitive hippocampal pathway and an antidepressant-sensitive model."

Journal • Preclinical • CNS Disorders • Epilepsy • Mental Retardation • Psychiatry • GRIN2B

A Study to Evaluate Lu AF90103 in Healthy Men (clinicaltrials.gov) - P1 | N=15 | Terminated | Sponsor: H. Lundbeck A/S | N=92 ➔ 15 | Recruiting ➔ Terminated; The study was terminated based on new safety data.

Enrollment change • Trial termination

A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: H. Lundbeck A/S | Recruiting ➔ Completed

Trial completion

A Study to Evaluate Lu AF90103 in Healthy Men (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: H. Lundbeck A/S | Trial completion date: Aug 2022 ➔ Nov 2022 | Trial primary completion date: Apr 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date